CAR T-cell Therapy in Multiple Myeloma: Finding Its Right Place - Episode 9

Clinical Perspectives: Importance of Vaccinations and Infection Prevention Post CAR T, and Monitoring Strategies for Other Potential Late CAR T–Related Toxicities in R/R MM

April 28, 2025

Surbhi Sidana, MD, Peter Voorhees, MD, Atrium Health

Experts discuss strategies for managing and mitigating early vs late chimeric antigen receptor (CAR) T-cell therapy–related toxicities, offering advice to practitioners, and share additional clinical pearls on improving the overall CAR T process in academic and community settings.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Optimizing CAR T in R/R MM: Treatment Paradigms and Patient Selection

EP. 2: Sequencing CAR T in More Heavily Pretreated R/R MM as well in patients who deferred initial autologous HSCT

EP. 3: Cilta-cel vs. Ide-cel: Key Data Updates and Clinical Decision-Making in R/R MM

EP. 4: Strategic Timing for CAR T in R/R MM: The Importance of Early Referral

EP. 5: Bridging to CAR T in R/R MM: Best Practices

EP. 6: Explaining CAR T: Key Points for Patient Counseling

EP. 7: Overcoming Barriers to CAR T Referral in R/R MM

EP. 8: Collaborative Approach in Managing Post CAR T Care Between Academic and Community Physicians in R/R MM

Now Viewing

EP. 9: Clinical Perspectives: Importance of Vaccinations and Infection Prevention Post CAR T, and Monitoring Strategies for Other Potential Late CAR T–Related Toxicities in R/R MM

EP. 10: Exciting Future Horizons for CAR T in MM and Take-Home Messages

Video content above is prompted by the following:

What strategies would you advise other practitioners regarding managing and mitigating early vs late CAR T–related toxicities?
Please share any additional clinical pearls or perspectives on how the overall CAR T process can improve in both the academic and community setting